Fatty Acid

Docosahexaenoic Acid

Docosahexaenoic acid

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

500-1000 mg/day

watchEffect Window

weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Docosahexaenoic Acid provide omega 3 fatty acids that influence membrane composition and eicosanoid signaling. They are used for triglyceride lowering and inflammatory balance.

Omega 3 trials consistently reduce triglycerides and can lower high sensitivity CRP in some populations. Effects on depression, arthritis pain, and cognition are mixed and often dose dependent. Minority evidence includes improved dry eye and exercise recovery. Bleeding risk is usually small but can matter with anticoagulants and very high doses.

DHA supports neuronal and membrane function. Strongest confidence in biological/biomarker outcomes, lower for direct acute cognitive gains.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Structural neural support markers
  • Triglyceride reduction potential

Secondary Outcomes

  • Modest mood/cognitive support in selected contexts
  • Anti-inflammatory balance trends

Safety

Contraindications and Interactions

Contraindications

  • Active bleeding disorder
  • Fish/shellfish allergy
  • Planned surgery without clinician guidance

Side effects

  • Fishy burps
  • Mild GI upset
  • Minor bleeding tendency at higher doses

Interactions

  • Anticoagulants/antiplatelet agents
  • Other omega-3 concentrated products

Avoid if

  • Severe coagulopathy
  • Uncontrolled fish oil contamination sensitivity
  • Surgery planned soon

Evidence

Study-level References

docosahexaenoic-acid-SRC-001Meta-analysis and RCTs
Sourceopen_in_new

PMID: 32690472

Population: Diverse adult and maternal cohorts

Dose protocol: Omega-3 supplementation with DHA-containing formulas

Key findings: Modest positive shifts in selected symptom domains. Neutral overall for many healthy performance tasks.

Notes: Heterogeneity in dose, duration, co-ingredients, and baseline deficiency states.

Paper content

Modest positive shifts in selected symptom domains; neutral overall for many healthy performance tasks.

docosahexaenoic-acid-SRC-002RCT and cohort synthesis
Sourceopen_in_new

PMID: 31383846

Population: Cardiovascular and general adult populations

Dose protocol: Structured omega-3 dosing regimens

Key findings: Reliable triglyceride reduction in many cohorts. Bleeding-risk signals low but present.

Notes: Dose and co-supplement contamination are common confounders.

Paper content

Reliable triglyceride reduction in many cohorts; bleeding-risk signals low but present.

docosahexaenoic-acid-SRC-003Meta-analysis of prospective cohort studies.
Sourceopen_in_new

Wei BZ, Li L, Dong CW, Tan CC, Xu W; Alzheimer's Disease Neuroimaging Initiative. The relationship of omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. Am J Clin Nutr. 2023;117(6):1096-1109. doi:10.1016/j.ajcnut.2023.04.001. PMID:37028557.

Population: Older adults from 48 prospective longitudinal studies plus 1,135 ADNI participants.

Dose protocol: Omega-3 supplementation, dietary intake, and blood markers across 48 prospective studies

Key findings: Long-term omega-3 supplement users showed 64% reduced AD risk. Each 0.1 g/day DHA increment correlated with 8-10% lower cognitive decline risk.

Notes: Observational meta-analysis. Cannot establish causation but dose-response relationship is consistent.

Paper content

This large meta-analysis combined data from 48 prospective longitudinal studies (103,651 participants) and 1,135 ADNI participants to examine the relationship between omega-3 fatty acids and cognitive outcomes. Long-term omega-3 supplement users showed a 64% reduced risk of Alzheimer's disease. Higher dietary omega-3 intake was associated with approximately 20% lower risk of dementia and cognitive decline. Each 0.1 g/day increment of DHA or EPA correlated with 8 to 10% lower cognitive decline risk. The study is observational and cannot establish causation, but the dose-response relationship and consistency across multiple evidence types (supplementation, diet, biomarkers) strengthen the signal.

Guides

Setup

Help